CORDIS
EU research results

CORDIS

English EN
New nanomaterials for neural stem cells drug delivery

New nanomaterials for neural stem cells drug delivery

Objective

Brain conditions such as neurodegenerative diseases, stroke and traumatic injuries are a mayor burden in modern society. Because neural stem cells (NSCs) can differentiate into new neural cells including neurons, the regulation of their proliferation, differentiation and migration represent a promising regenerative/therapeutic strategy. The hypothesis of NanoStem project is that novel nanoparticles (NPs) combined with recent identified/developed pharmaceuticals can be an efficient approach to control the biological activity of NSCs. The scientific project is organized in three work packages (WP), each focusing on specific objectives and containing well-defined deliverables. WP1 will focus on the synthesis of the nanomaterials and the uploading of the therapeutics. WP2 will take the best nanoparticles and focus more on the evaluation of the permeation and efficacy of the formulations against NSCs. WP3 will focus on in vivo studies to evaluate the formulations developed to tackle the brain and to assess their toxicity. The project will train 14 ESRs in areas including organic and polymer chemistry, cell biology, pharmacology, neuroscience, nanobiotechnology and clinical sciences. The project will also provide a substantial training program in complementary skills, targeting both professional and personal development, and translation of research and entrepreneurship. The project brings together six academic partners, one hospital and two industrial teams as full partners, complemented by four associate partners, one of which is an industrial team, distributed over a total of seven European Union member states. The consortium brings together groups with a very interdisciplinary expertise ranging from nanoparticle synthesis and characterization, computational modeling, in vitro BBB models and BBB transport, neural stem cells, animal testing and clinical expertise.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

QUEEN MARY UNIVERSITY OF LONDON

Address

327 Mile End Road
E1 4ns London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 819 863,64

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO

Portugal

EU Contribution

€ 715 069,08

UNIVERSITE D'ARTOIS

France

EU Contribution

€ 525 751,20

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 263 659,32

CENTRO HOSPITALAR E UNIVERSITARIO DE COIMBRA E.P.E.

Portugal

EU Contribution

€ 238 356,36

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 249 216,48

MJR PHARMJET GMBH

Germany

EU Contribution

€ 249 216,48

UNIVERSITAET INNSBRUCK

Austria

EU Contribution

€ 255 934,08

THE UNIVERSITY OF WARWICK

United Kingdom

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 273 287,88

Partners (4)

Sort alphabetically

Expand all

HCS-Pharma

BRAINS FOR BRAIN FOUNDATION ONLUS

UNIVERSITAT DES SAARLANDES

UNIVERSIDADE DE COIMBRA

Project information

Grant agreement ID: 764958

Status

Ongoing project

  • Start date

    1 June 2018

  • End date

    31 May 2022

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 590 354,52

  • EU contribution

    € 3 590 354,52

Coordinated by:

QUEEN MARY UNIVERSITY OF LONDON

United Kingdom